2024-10-12 - Analysis Report
## AbbVie Inc (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a multinational pharmaceutical company that develops and markets a diverse range of therapies, primarily focusing on immunology, oncology, and neurology.

**Performance Analysis:**

* **Return:** ABBV has generated a cumulative return of 151.86% compared to the S&P 500 (VOO) which returned 134.11%. This means ABBV has outperformed the market by 17.75%. 
* **Relative Strength:** ABBV's relative strength compared to the S&P 500 is currently at 59.13%, indicating that its performance is currently above 59.13% of its historical performance range compared to the S&P 500.
* **Price Trend:** The closing price for ABBV is $193.77. 
    * 5-day moving average: $193.89
    * 20-day moving average: $194.26
    * 60-day moving average: $191.34
    * ABBV's price is currently slightly below its 5-day and 20-day moving averages, indicating a potential short-term downward trend. However, the 60-day moving average suggests a longer-term bullish trend.
* **Technical Indicators:**
    * RSI (Relative Strength Index): 50.87. This value indicates that ABBV is currently trading in a neutral territory, neither oversold nor overbought.
    * PPO (Percentage Price Oscillator): -0.15. This value indicates that the price momentum is currently slightly bearish.
    * **Delta_Previous_Relative_Divergence:** -6.46. This negative value indicates that ABBV's relative strength has decreased in the past 20 days, suggesting a potential short-term downtrend.
    * **Expected Return:** 1.62%. This indicates that ABBV is expected to outperform the S&P 500 by 1.62% over the next five years.
* **Recent Earnings:** ABBV exceeded analysts' earnings expectations in the last two quarters. 
    * The most recent earnings report for Q2 2024 showed an EPS of $2.65, surpassing the estimated EPS of $2.57. 
    *  This consistent outperformance suggests strong financial performance and positive market sentiment.

**News and Recent Issues:**

* **Recent Market Outlook:** AbbVie has been performing relatively well, with the stock price seeing a slight downward trend in recent days. However, the stock has been holding up well against the broader market decline and is generally considered a strong performer.
* **Analyst Opinions:** Many analysts remain optimistic about AbbVie's prospects. They cite the company's strong drug pipeline, including promising new treatments for autoimmune diseases and cancer. 
* **Performance Highlights:**  ABBV's strong revenue growth and consistent profitability continue to attract investors.  The company's focus on developing innovative therapies for high-demand therapeutic areas, coupled with a strong market position, positions it well for continued success in the future.

**Conclusion:** 

ABBV shows promising potential for investors seeking exposure to the pharmaceutical sector. The company's strong fundamentals, supported by its innovative drug pipeline, promising new treatments, and consistent outperformance in recent earnings, suggest long-term growth opportunities. However, it's important to note that the stock has shown a slight downward trend in recent days, potentially influenced by broader market volatility.  Investors should consider their individual risk tolerance and investment objectives before making any investment decisions. 
